HomeCompareINTEW vs ABBV

INTEW vs ABBV: Dividend Comparison 2026

INTEW yields 4008.02% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 INTEW wins by $7315228831689.48M in total portfolio value
10 years
INTEW
INTEW
● Live price
4008.02%
Share price
$0.05
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$7315228831689.58M
Annual income
$6,972,991,438,836,355,000.00
Full INTEW calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — INTEW vs ABBV

📍 INTEW pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodINTEWABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, INTEW + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
INTEW pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

INTEW
Annual income on $10K today (after 15% tax)
$340,681.36/yr
After 10yr DRIP, annual income (after tax)
$5,927,042,723,010,902,000.00/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, INTEW beats the other by $5,927,042,723,010,881,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of INTEW + ABBV for your $10,000?

INTEW: 50%ABBV: 50%
100% ABBV50/50100% INTEW
Portfolio after 10yr
$3657614415844.84M
Annual income
$3,486,495,719,418,190,000.00/yr
Blended yield
95.32%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

INTEW
No analyst data
Altman Z
-2.9
Piotroski
4/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

INTEW buys
0
ABBV buys
7
PoliticianChamberTickerTypeAmountDate
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-12-18
Julia Letlow🏢 House$ABBV▼ Sell$1,001 - $15,0002025-12-08
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-11-13
Lisa McClain🏢 House$ABBV▼ Sell$1,001 - $15,0002025-10-31
Lisa McClain🏢 House$ABBV▼ Sell$1,001 - $15,0002025-10-30
Lisa McClain🏢 House$ABBV▲ Buy$1,001 - $15,0002025-10-30
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-22
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-22
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-08-14
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-11
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricINTEWABBV
Forward yield4008.02%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$7315228831689.58M$102.3K
Annual income after 10y$6,972,991,438,836,355,000.00$24,771.77
Total dividends collected$7291885191190.73M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: INTEW vs ABBV ($10,000, DRIP)

YearINTEW PortfolioINTEW Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$411,502$400,801.60$11,550$430.00+$400.0KINTEW
2$15,854,372$15,414,065.63$13,472$627.96+$15.84MINTEW
3$571,987,137$555,022,958.83$15,906$926.08+$571.97MINTEW
4$19,325,929,473$18,713,903,236.02$19,071$1,382.55+$19325.91MINTEW
5$611,606,963,503$590,928,218,966.76$23,302$2,095.81+$611606.94MINTEW
6$18,132,067,236,656$17,477,647,785,708.22$29,150$3,237.93+$18132067.21MINTEW
7$503,656,302,118,131$484,254,990,174,908.75$37,536$5,121.41+$503656302.08MINTEW
8$13,110,127,960,405,216$12,571,215,717,138,816.00$50,079$8,338.38+$13110127960.36MINTEW
9$319,848,030,703,946,600$305,820,193,786,313,000.00$69,753$14,065.80+$319848030703.88MINTEW
10$7,315,228,831,689,580,000$6,972,991,438,836,355,000.00$102,337$24,771.77+$7315228831689.48MINTEW

INTEW vs ABBV: Complete Analysis 2026

INTEWStock

Integral Acquisition Corporation 1 intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. It intends to target a business combination with a technology-oriented company in Australia and/or New Zealand. The company was incorporated in 2021 and is based in New York, New York.

Full INTEW Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this INTEW vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

INTEW vs SCHDINTEW vs JEPIINTEW vs OINTEW vs KOINTEW vs MAININTEW vs JNJINTEW vs MRKINTEW vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.